Back
A Pilot Study of Gemcitabine and Epirubicin Combination Chemotherapy as a Salvage Regimen for Recurrent Platinum Resistant and/or Refractory Epithelial Ovarian Cancer
Abd El Halim Abu-Hamar
J. Cancer Ther. Vol.2 No.4, October 12, 2011  DOI: 10.4236/jct.2011.24066
       (PDF  165K)     HTML     
Target Therapy in Platinum-Refractory/Resistant Ovarian Cancer: From Preclinical Findings to Current Clinical Practice
Nicoletta Staropoli, Cirino Botta, Domenico Ciliberto, Lucia Fiorillo, Antonina Maria De Angelis, Caterina Viscomi, Simona Gualtieri, Angela Salvino, Pierfrancesco Tassone, Pierosandro Tagliaferri
J. Cancer Ther. Vol.4 No.5, July 09, 2013  DOI: 10.4236/jct.2013.45115
       (PDF  552K)     HTML     
Occurrence of myelodysplastic syndrome during paclitaxel- and carboplatin-based chemotherapy for recurrent ovarian cancer: Case report
Hiroshi Takagi, Satoshi Ichigo, Kazutoshi Matsunami, Haruna Takagi, Tsuneko Ikeda, Takayuki Murase, Atsushi Imai
Open J. Obstet. Gynecol. Vol.3 No.2, March 13, 2013  DOI: 10.4236/ojog.2013.32043
       (PDF  246K)     HTML      XML
A young women with a large ovarian mass
Vicky O’Dwyer, Kevin Hickey
Open J. Obstet. Gynecol. Vol.3 No.1, January 11, 2013  DOI: 10.4236/ojog.2013.31008
       (PDF  32K)     HTML      XML
Triple Negative Breast Cancer Treatment: Use of Platinum and Platinum Analogs
Manuela Fantini, Carlotta Santelmo, Fabrizio Drudi, Claudio Ridolfi, Eleonora Barzotti, Lorenzo Gianni, Valentina Arcangeli, Alessandra Affatato, Alberto Ravaioli
J. Cancer Ther. Vol.3 No.5, November 01, 2012  DOI: 10.4236/jct.2012.325097
       (PDF  73K)     HTML     
 
 
Top